AR049999A1 - Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria. - Google Patents
Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria.Info
- Publication number
- AR049999A1 AR049999A1 ARP050103004A ARP050103004A AR049999A1 AR 049999 A1 AR049999 A1 AR 049999A1 AR P050103004 A ARP050103004 A AR P050103004A AR P050103004 A ARP050103004 A AR P050103004A AR 049999 A1 AR049999 A1 AR 049999A1
- Authority
- AR
- Argentina
- Prior art keywords
- apoptosis
- eif
- specific
- antisense oligonucleotide
- cell
- Prior art date
Links
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 title abstract 6
- 230000006907 apoptotic process Effects 0.000 title abstract 4
- 230000028709 inflammatory response Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 5
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 5
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 abstract 3
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005265 lung cell Anatomy 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Método para suprimir o reducir la apoptosis en una célula administrando un agente que inhibe o reduce la expresion del eIF-5A de la apoptosis o de la DHS (deoxihiposina sintasa). Un oligonucleotido antisentido del eIF-5A específico de la apoptosis en donde el oligonucleotido antisentido suprime la expresion endogena del eIF-5A específico de la apoptosis en una célula. Dicho oligonucleotido antisentido en donde el eIF-5A específico de la apoptosis se codifica con una secuencia de nucleotidos de la SEQ ID N. 20, 41, 35, 37 o 39. Un vector de expresion para la transfeccion de una célula de mamífero que comprende dicho oligonucleotido antisentido y secuencias reguladoras unidas en forma operativa al oligonucleotido antisentido en dicha célula. Método de inhibir la expresion del eIF-5A específico de la apoptosis en una célula. Método que administra siARN a las células pulmonares de un mamífero in vivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58907304P | 2004-07-20 | 2004-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049999A1 true AR049999A1 (es) | 2006-09-20 |
Family
ID=35787722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103004A AR049999A1 (es) | 2004-07-20 | 2005-07-20 | Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060154887A1 (es) |
| EP (1) | EP1769075A2 (es) |
| JP (1) | JP2008507278A (es) |
| CN (1) | CN101027393A (es) |
| AR (1) | AR049999A1 (es) |
| AU (1) | AU2005269647B2 (es) |
| CA (1) | CA2574190A1 (es) |
| IL (1) | IL180802A0 (es) |
| NZ (1) | NZ552692A (es) |
| TW (1) | TW200615001A (es) |
| WO (1) | WO2006014752A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007109674A2 (en) * | 2006-03-20 | 2007-09-27 | Senesco Technologies, Inc. | Use of eif-5a1 sirna and antisense to treat sepsis or haemorrhagic shock |
| WO2007115047A2 (en) * | 2006-03-29 | 2007-10-11 | Senesco Technologies, Inc. | Inhibition of hiv replication and expression of p24 with eif-5a |
| CN103709238B (zh) * | 2013-12-18 | 2015-04-22 | 北京市农林科学院 | 杨树耐盐基因PtoeIF5A1的应用 |
| KR101993377B1 (ko) * | 2017-07-20 | 2019-06-26 | (주)큐리진 | Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849587A (en) * | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| US6468983B2 (en) * | 1997-04-21 | 2002-10-22 | The Cleveland Clinic Foundation | RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| US7358418B2 (en) * | 1999-07-06 | 2008-04-15 | Senesco Technologies, Inc. | Isoforms of eIF-5A: senescence-induced eLF5A; wounding-induced eIF-4A; growth eIF-5A; and DHS |
| US6033910A (en) * | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| US7381708B2 (en) * | 2001-07-23 | 2008-06-03 | Sensco Technologies, Inc. | Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
| US7217517B2 (en) * | 2001-07-23 | 2007-05-15 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, and methods for modulating apoptosis |
| US7968523B2 (en) * | 2001-07-23 | 2011-06-28 | Senesco Technologies, Inc. | Method for inducing apoptosis using apoptosis-specific EIF5-A |
| US7166467B2 (en) * | 2001-07-23 | 2007-01-23 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| CA2462638A1 (en) * | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
| NZ542665A (en) * | 2003-03-05 | 2008-05-30 | Senesco Technologies Inc | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| WO2005007853A2 (en) * | 2003-06-06 | 2005-01-27 | Senesco Technologies, Inc. | Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics |
-
2005
- 2005-07-20 EP EP05790728A patent/EP1769075A2/en not_active Withdrawn
- 2005-07-20 AR ARP050103004A patent/AR049999A1/es unknown
- 2005-07-20 CN CNA2005800314879A patent/CN101027393A/zh active Pending
- 2005-07-20 TW TW094124618A patent/TW200615001A/zh unknown
- 2005-07-20 JP JP2007522708A patent/JP2008507278A/ja active Pending
- 2005-07-20 US US11/184,982 patent/US20060154887A1/en not_active Abandoned
- 2005-07-20 AU AU2005269647A patent/AU2005269647B2/en not_active Ceased
- 2005-07-20 WO PCT/US2005/025766 patent/WO2006014752A2/en active Application Filing
- 2005-07-20 CA CA002574190A patent/CA2574190A1/en not_active Abandoned
- 2005-07-20 NZ NZ552692A patent/NZ552692A/en unknown
-
2007
- 2007-01-18 IL IL180802A patent/IL180802A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101027393A (zh) | 2007-08-29 |
| AU2005269647A1 (en) | 2006-02-09 |
| NZ552692A (en) | 2010-08-27 |
| AU2005269647B2 (en) | 2009-11-12 |
| WO2006014752A3 (en) | 2006-06-01 |
| JP2008507278A (ja) | 2008-03-13 |
| CA2574190A1 (en) | 2006-02-09 |
| IL180802A0 (en) | 2007-06-03 |
| US20060154887A1 (en) | 2006-07-13 |
| EP1769075A2 (en) | 2007-04-04 |
| WO2006014752A2 (en) | 2006-02-09 |
| TW200615001A (en) | 2006-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buckingham et al. | The role of telomeres in the ageing of human skin | |
| El Azzouzi et al. | The hypoxia-inducible microRNA cluster miR-199a∼ 214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation | |
| PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
| Sado et al. | Advances in understanding chromosome silencing by the long non-coding RNA Xist | |
| CO6251331A2 (es) | Inhibicion de arni de expresion de alfa-enac | |
| PE20211393A1 (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO | |
| He et al. | Long noncoding RNA HIF1A-AS1A reduces apoptosis of vascular smooth muscle cells: implications for the pathogenesis of thoracoabdominal aorta aneurysm. | |
| WO2005087926A3 (en) | Multiple promoter expression cassettes for simultaneous delivery of rnai agents | |
| ES2570382T3 (es) | Composiciones y métodos para la producción de azúcares fermentables | |
| AR078848A1 (es) | Tecnologia terapeutica de arn de interferencia dirigido al oncogen pdx -1 en tumores neuroendocrinos donde se expresa pdx-1 | |
| Zhang et al. | RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity | |
| NZ587809A (en) | Use of mesenchymal stem cells expressing cd73 and/or cd105 for treating genetic diseases and disorders | |
| AR049999A1 (es) | Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria. | |
| PE20230179A1 (es) | Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt) | |
| WO2012008301A1 (ja) | ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法 | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| JP2018088923A (ja) | 線維症予防又は治療剤 | |
| WO2013019857A3 (en) | Method for improving the success rate of hematopoietic stem cell transplants | |
| AR073274A1 (es) | Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas | |
| Schmoeckel et al. | Transgenic human decay accelerating factor makes normal pigs function as a concordant species. | |
| Wei et al. | Highly potent and stable capped siRNAs with picomolar activity for RNA interference. | |
| AR079649A1 (es) | Composiciones y metodos para inhibir la expresion de genes il-18 | |
| Phillips et al. | Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies | |
| KR20170063263A (ko) | miRNA를 포함하는 흑색종 전이 억제용 조성물 | |
| US20180264141A1 (en) | A method effective to modulate expression of t-box protein 4 (tbx4) for reducing progression of lung fibrosis after a lung injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |